

# Contents

## **PART I THE BACKGROUND TO PHARMACEUTICALS**

|                                                              |           |
|--------------------------------------------------------------|-----------|
| <b>1. History</b>                                            | <b>3</b>  |
| <b>2. The Characteristics of the Pharmaceutical Industry</b> | <b>18</b> |
| 2.1 The World Pharmaceutical Industry / 18                   |           |
| 2.2 The Pharmaceutical Industry in the U.S. Economy / 22     |           |
| 2.3 Profitability / 23                                       |           |
| 2.4 Capital Investment / 24                                  |           |
| 2.5 Research Expenditure / 25                                |           |
| 2.6 Employment / 28                                          |           |
| 2.7 Patent Protection / 29                                   |           |
| 2.8 Competition and Promotion / 30                           |           |
| 2.9 Manufacture of Products / 30                             |           |
| 2.10 Drug Testing / 32                                       |           |
| 2.11 Drug Nomenclature and Generic Drugs / 36                |           |
| 2.11.1 <i>Generic versus Branded Pharmaceuticals</i> / 38    |           |
| <b>3. Patterns of Illness and Health Care</b>                | <b>41</b> |
| 3.1 Ethical and Over-the-Counter Drugs / 41                  |           |
| 3.2 Physicians / 42                                          |           |
| 3.3 Patients / 44                                            |           |
| 3.3.1 <i>Mortality</i> / 44                                  |           |
| 3.3.2 <i>Disability</i> / 48                                 |           |

3.3.3 *Visits to the Physician* / 50

3.3.4 *Prescribing Drugs* / 52

3.3.5 *Correlation* / 55

#### 4. Pharmacological Concepts

56

4.1 Receptor Theory / 56

4.1.1 *Enzymes* / 57

4.1.2 *Nucleic Acids* / 58

4.1.3 *Permeases* / 60

4.2 Radioligands / 61

4.2.1 *Receptor Geometry* / 64

4.3 Replacements, Redesigned Agonists, and Antagonists / 65

4.3.1 *Agonists* / 65

4.3.2 *Antagonists* / 66

4.3.3 *Drug Design* / 69

4.3.4 *Structure-Activity Relations* / 70

4.4 What Happens to Drugs in the Body / 72

4.5 Drug Absorption and Dosage Forms / 74

4.5.1 *Enteral Dosage* / 74

4.5.2 *Percutaneous Dosage* / 76

4.5.3 *Inhalation* / 77

4.5.4 *Parenteral Dosage* / 78

4.5.5 *Other Dosage Forms* / 79

4.6 Drug Distribution / 81

4.6.1 *Binding to Plasma Protein and Blood Cells* / 81

4.6.2 *Physical Properties of the Drug* / 82

4.6.3 *Other Factors* / 82

4.7 Biotransformation of Drugs / 83

4.8 Excretion / 88

4.9 Bioavailability and the Digoxin Affair / 88

4.10 Properties of an Ideal Drug / 91

4.11 Conclusion / 93

## PART II: THE TOP-100 DRUGS

### 5. The Production of Pharmaceuticals

97

5.1 The Top-100 Drugs / 97

5.2 Classification of Drugs / 101

5.3 Sources of Drugs / 104

- 5.4 Manufacturing Processes / 106
  - 5.4.1 *Quality Control* / 106
  - 5.4.2 *Choice of Reagents* / 108
  - 5.4.3 *Plant Design* / 108
  - 5.4.4 *Cost Structure* / 109

## 6. Antibacterials and Antibiotics

111

- 6.1 Classification of Bacteria / 113
- 6.2 Sulfonamides / 115
- 6.3 Penicillins / 120
  - 6.3.1 *Penicillin Manufacture* / 126
  - 6.3.2 *Improving Penicillins* / 128
  - 6.3.3 *Semisynthetic Penicillins* / 130
  - 6.3.4 *Production of 6-Aminopenicillanic Acid* / 132
  - 6.3.5 *Production of Ampicillin and Amoxycillin* / 133
  - 6.3.6 *Penicillin Esters* / 134
  - 6.3.7  *$\beta$ -Lactamase Inhibitors* / 138
  - 6.3.8 *The Future of Penicillins* / 139
- 6.4 Cephalosporins / 142
  - 6.4.1 *Manufacture of Cephalosporins* / 145
  - 6.4.2 *7-Oximinoacylcephalosporins* / 148
  - 6.4.3 *Cepharmycin C Derivatives* / 151
  - 6.4.4 *Cephalosporins in Hospitals* / 152
- 6.5 Tetracyclines / 152
  - 6.5.1 *Manufacture of Tetracyclines* / 154
  - 6.5.2 *Rolitetracycline* / 156
- 6.6 Macrolide Antibiotics / 157
- 6.7 Aminoglycosides and Antituberculosis Drugs / 158
  - 6.7.1 *Tuberculosis Therapy* / 159
- 6.8 Peptide Antibiotics / 162
- 6.9 Quinolone Antibacterials / 163
- 6.10 Miscellaneous Antibacterials / 164
  - 6.10.1 *Chloramphenicol and Nitrofurantoin* / 164
  - 6.10.2 *Lincomycin and Clindamycin* / 167
  - 6.10.3 *Vancomycin* / 168
- 6.11 Antifungals / 168
- 6.12 The Future / 170

## 7. Cardiovascular Drugs

174

- 7.1 The Functioning of the Heart / 174
  - 7.1.1 *Diseases of the Heart* / 177

- 7.2 Cardiac Glycosides / 179
- 7.3 Antiarrhythmics / 180
- 7.4 Diuretics / 182
  - 7.4.1 *Carbonic Anhydrase Inhibitors* / 184
  - 7.4.2 *Low-Ceiling Diuretics* / 184
  - 7.4.3 *High-Ceiling (Loop) Diuretics* / 187
  - 7.4.4 *Potassium-Sparing Diuretics* / 188
  - 7.4.5 *Potassium Replenishers* / 192
- 7.5 Coronary Vasodilators and  $\beta$ -Adrenergic Agents / 192
  - 7.5.1 *Nitrates and Nitrites* / 193
  - 7.5.2 *Calcium Antagonists* / 194
  - 7.5.3 *Hemorheologic Agent* / 196
  - 7.5.4 *Mode of Action of  $\beta$ -Adrenergic Agents* / 197
  - 7.5.5  *$\beta$ -Adrenergic Drugs* / 200
  - 7.5.6  *$\beta$ -Adrenergic Blocking Drugs* / 203
  - 7.5.7  *$\alpha$ - and  $\beta$ -Adrenergic Drug* / 207
- 7.6 Antihypertensive Agents / 207
  - 7.6.1 *Centrally Acting Antihypertensives* / 207
  - 7.6.2 *Vasodilators* / 211
  - 7.6.3 *Adrenergic Neuron Blockers* / 212
  - 7.6.4 *Angiotensin-Converting Enzyme Inhibitors* / 212
- 7.7 Anticoagulants / 214
- 7.8 Thrombolytic Agents / 218
- 7.9 Hypolipemics / 219
- 7.10 Conclusion / 222

## 8. Drugs Affecting the Central Nervous System

224

- 8.1 Hypnotics and Sedatives / 227
  - 8.1.1 *Barbiturates* / 227
  - 8.1.2 *Nonbarbiturate Hypnotics and Sedatives* / 229
  - 8.1.3 *Anticonvulsants* / 231
- 8.2 Major Tranquilizers (Neuroleptics) / 233
- 8.3 Anxiolytics (Minor Tranquilizers) / 238
  - 8.3.1 *Benzodiazepines* / 240
  - 8.3.2 *Benzodiazepine Syntheses* / 243
  - 8.3.3 *Meprobamate, Hydroxyzine, and Buspirone* / 248
  - 8.3.4 *Benzodiazepine Antagonists and Mode of Action* / 249
- 8.4 Antidepressants / 253
  - 8.4.1 *Monoamine Oxidase Inhibitors* / 253
  - 8.4.2 *Tricyclic Antidepressants* / 255
  - 8.4.3 *Tetracyclic Antidepressants* / 258
  - 8.4.4 *Serotonin Reuptake Inhibitors* / 261

## 8.5 Stimulants and Appetite Suppressants / 263

8.5.1 *Amphetamine-like Anorectics* / 2648.5.2 *Caffeine and Cocaine* / 266

## 8.6 Psychotomimetics / 268

## 8.7 Use and Abuse / 270

**9. Antihistamines** **274**

## 9.1 Allergy / 274

## 9.2 Antiallergy and Antinausea Compounds / 276

## 9.3 Nonsoporific Antihistamines / 279

9.4 Syntheses of  $H_1$  Blockers / 280

## 9.5 "Cold Cures" / 282

9.6  $H_2$ -Blocking Antihistamines and Antiulcer Drugs / 2849.6.1 *Syntheses of  $H_2$  Blockers* / 2899.6.2 *Other Antiulcer Drugs* / 289**10. Analgesics** **292**

## 10.1 Narcotic Analgesics / 292

10.1.1 *Antidiarrhea Drugs* / 29410.1.2 *Methadone and Propoxyphene* / 29710.1.3 *Morphine Antagonists* / 30010.1.4 *Opioid Receptors* / 30110.1.5 *Etorphine* / 30110.1.6 *Buprenorphine* / 30310.1.7 *Oxycodone, Hydrocodone, Dihydrocodeine,  
and Dextromethorphan* / 304

## 10.2 Nonnarcotic Pain Relievers / 305

10.2.1 *Aspirin* / 30710.2.2 *Acetaminophen (Paracetamol)* / 308

## 10.3 Endorphins and Enkephalins / 310

**11. Steroid Drugs** **314**

## 11.1 Natural Steroids / 314

## 11.2 Conjugated Estrogenic Hormone / 317

## 11.3 Oral Contraceptives / 318

11.3.1 *Progesterone Antagonist* / 32011.3.2 *Risks of Oral Contraceptives* / 321

## 11.4 Anti-inflammatory Steroids / 323

## 11.5 Other Applications of Steroids / 325

## 11.6 Manufacture of Steroids / 325

11.6.1 *Steroids from Diosgenin* / 327

11.6.2 *Steroids from Stigmasterol* / 328

11.6.3 *Steroids from Sitosterol* / 330

## 12. Nonsteroid Anti-inflammatory Agents 334

12.1  $\alpha$ -Arylpropionic Acids / 336

12.1.1 *Syntheses of Ibuprofen* / 337

12.1.2 *Syntheses of Naproxen* / 342

12.1.3 *Synthesis of Fenoprofen* / 345

12.2 Substituted Acetic Acid Derivatives / 346

12.3 Enolic  $\beta$ -Diketones / 346

12.4 Anthranilic/Salicylic Acid Derivatives / 350

12.5 Other Anti-inflammatories / 350

12.6 Conclusion / 351

## 13. Hypoglycemics 353

13.1 Replacement Therapy / 354

13.2 Insulin via Recombinant DNA / 354

13.3 Oral Hypoglycemics / 357

13.3.1 *Syntheses of Oral Hypoglycemics* / 359

13.4 Recent Developments / 361

## 14. Anticholinergic Drugs 363

14.1 The Solanaceous Alkaloids / 366

14.2 Dicyclomine / 366

14.3 Clidinium Bromide / 367

## 15. Antiasthma Drugs 369

15.1  $\beta$ -Adrenergic Agonists / 370

15.1.1 *Syntheses of  $\beta_2$  Agonists* / 373

15.2 Methylxanthine Bronchodilators / 375

15.3 Disodium Cromoglycate / 377

15.3.1 *Dosage Forms* / 378

15.4 Steroids / 379

15.5 Leukotriene Inhibitors / 379

## 16. Parkinson's Disease 380

16.1 Asymmetric Synthesis of Levodopa / 381

16.2 Effects of Levodopa / 383

16.3 Other Drugs / 384

16.4 Huntingdon's Chorea / 385

**17. Miscellaneous Drugs 387**

- 17.1 Thyroid Hormones / 387
- 17.2 Muscle Relaxants / 389
- 17.3 Allopurinol / 390
- 17.4 Antismoking Drug / 391
- 17.5 Acne Treatment / 391
- 17.6 Metoclopramide / 392
- 17.7 Vitamins / 393
  - 17.7.1 Vitamin C / 393
  - 17.7.2 Vitamin A / 396
  - 17.7.3 Vitamin B<sub>12</sub> / 397

**PART III DRUG GROUPS OUTSIDE THE TOP-100****18. Tropical Diseases 401**

- 18.1 Insecticides / 403
- 18.2 Antiprotozoals / 404
  - 18.2.1 Malaria / 404
  - 18.2.2 Trypanosomiasis and Leishmaniasis / 410
  - 18.2.3 Amebiasis and Trichomoniasis / 411
- 18.3 Helminth Infections / 413
  - 18.3.1 Drugs against Nematodes / 414
  - 18.3.2 Drugs against Trematodes / 416
- 18.4 Tuberculosis, Cholera, Typhoid Fever, Leprosy / 418
- 18.5 Yellow Fever and Hepatitis / 420
- 18.6 Conclusion / 421

**19. Prostaglandins 422**

- 19.1 The Arachidonic Acid Cascade / 423
  - 19.1.1 Prostaglandin Endoperoxides and Prostaglandins / 426
  - 19.1.2 Thromboxanes / 429
  - 19.1.3 Prostacyclin / 430
  - 19.1.4 Leukotrienes / 431
- 19.2 Prostaglandin Syntheses / 434
- 19.3 Novel Nonnarcotic Analgesics / 434
- 19.4 Steroids and Prostaglandins / 436

|                                                              |            |
|--------------------------------------------------------------|------------|
| <b>20. Antiviral Drugs</b>                                   | <b>438</b> |
| 20.1 Replication of Viruses / 439                            |            |
| 20.2 Virus Infections / 441                                  |            |
| 20.3 Pyrimidine and Purine Antimetabolites / 442             |            |
| 20.4 Amantadine / 444                                        |            |
| 20.5 Drugs against AIDS / 445                                |            |
| 20.6 Other Antiviral Drugs / 446                             |            |
| <b>21. Anticancer Drugs</b>                                  | <b>448</b> |
| 21.1 Origins of Cancer / 448                                 |            |
| 21.2 Prevention and Treatment / 451                          |            |
| 21.3 Steroids / 452                                          |            |
| 21.4 Alkylating Agents / 453                                 |            |
| 21.5 Antimetabolites / 454                                   |            |
| 21.6 Antibiotics / 456                                       |            |
| 21.7 Platinum Complexes / 457                                |            |
| 21.8 Miscellaneous Drugs / 458                               |            |
| <b>22. Orphan Drugs</b>                                      | <b>460</b> |
| <b>23. Innovations and Issues</b>                            | <b>463</b> |
| 23.1 New Chemical Entities 1986-1988 / 463                   |            |
| 23.2 The Achievement of the Pharmaceutical Industry / 467    |            |
| 23.3 The Problems of the Pharmaceutical Industry / 468       |            |
| 23.3.1 <i>Adverse Drug Reactions</i> / 468                   |            |
| 23.3.2 <i>Overprescribing</i> / 469                          |            |
| 23.3.3 <i>Are Profits Excessive?</i> / 469                   |            |
| 23.4 Drugs of the Future / 471                               |            |
| 23.5 Conclusion / 472                                        |            |
| <b>Appendixes</b>                                            |            |
| 1. The Most Widely Prescribed Drugs by Chemical Entity / 475 |            |
| 2. International Classification of Diseases / 478            |            |
| 3. Bibliography and Notes / 482                              |            |
| <b>Index</b>                                                 | <b>499</b> |